Skip to main content

Table 3 Comparison of the impact of relaxing different eligibility criteria in patients taking drug D2

From: The “RCT augmentation”: a novel simulation method to add patient heterogeneity into phase III trials

Re-included subpopulations

Natural augmentation (when opening the trial to the specific “real-world population” subgroup)

Prediction bias with natural augmentation

Mean squared error (MSE) of prediction with natural augmentation

Relaxed eligibility criteria

Illness duration between 1 and 3 years

56

0.004

0.733

1 past suicide attempt

73

0.013

0.734

Private practice

69

0.003

0.737

Alcohol abuse

42

−0.008

0.749

Drug abuse

22

−0.004

0.756

Illness duration between 1 and 3 years + 1 past suicide attempt

121

0.033

0.716

Illness duration between 1 and 3 years + private practice

121

0.009

0.719

Illness duration between 1 and 3 years + alcohol abuse

90

0.011

0.728

RCT population

not applicable

−0.016

0.777

SOHO “real-world population”

not applicable

0.000

0.000

  1. Results for the “RCT population” and SOHO “real-world populations” are displayed as benchmark